PBSV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PBSV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Pharma-Bio Serv's Trailing 12-Month Free Cash Flow is $-1.88 Mil, and Market Cap is $9.63 Mil. Therefore, Pharma-Bio Serv's FCF Yield % for today is -19.53%.
The historical rank and industry rank for Pharma-Bio Serv's FCF Yield % or its related term are showing as below:
During the past 13 years, the highest FCF Yield % of Pharma-Bio Serv was 30.84%. The lowest was -23.95%. And the median was 1.99%.
Pharma-Bio Serv's FCF Margin % for the quarter that ended in Jan. 2025 was -17.36%.
The historical data trend for Pharma-Bio Serv's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv Annual Data | |||||||||||||||||||||
Trend | Oct15 | Oct16 | Oct17 | Oct18 | Oct19 | Oct20 | Oct21 | Oct22 | Oct23 | Oct24 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
4.91 | 3.35 | 2.90 | 9.66 | -5.46 |
Pharma-Bio Serv Quarterly Data | ||||||||||||||||||||
Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | Apr24 | Jul24 | Oct24 | Jan25 | |
FCF Yield % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
13.17 | -16.61 | -18.01 | -2.37 | -12.46 |
For the Health Information Services subindustry, Pharma-Bio Serv's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Pharma-Bio Serv's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Pharma-Bio Serv's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Pharma-Bio Serv's FCF Yield % for the fiscal year that ended in Oct. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -0.727 | / | 13.31564 | |
= | -5.46% |
Pharma-Bio Serv's annualized FCF Yield % for the quarter that ended in Jan. 2025 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -0.429 | * | 4 | / | 13.7748 | |
= | -12.46% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma-Bio Serv FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Pharma-Bio Serv's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Elizabeth Plaza | 10 percent owner | 363 DORADO BEACH EAST, DORADO PR 00646 |
Altura Victor Sanchez | officer: President and CEO | C/O PHARMA-BIO SERV, INC., 6 ROAD 696, DORADO PR 00646 |
San Juan Holdings | 10 percent owner | 255 PONCE DE LEON, SUITE 305 MCS PLAZA, SAN JUAN PR 00917 |
Pedro J Lasanta | officer: Chief Financial Officer | 373 MENDEZ VIGO, STE 110, DORADO PR 00646 |
Dov Perlysky | director | 2 LAKESIDE DRIVE WEST, LAWRENCE NY 11559 |
L P Venturetek | 10 percent owner | C/O DAVID SELENGUT ELLENOFF GROSSMAN, 370 LEXINGTON AVENUE 19TH FLOOR, NEW YORK NY 10017 |
Barron Partners Lp | 10 percent owner | 730 FIFTH AVENUE, 25TH FLOOR, NEW YORK NY 10019 |
Manuel O Morera | officer: Chief Financial Officer | 373 MENDEZ VIGO, SUITE 110, DORADO PR 00646 |
Mark A Fazio | officer: Exec. Vice President and COO | P O BOX 1026 GREEN STREET, PERKASIE PA 18944 |
Kirk Wheeler Michel | director | 209 EAST TRYON STREET, HILLSBOROUGH NC 27278 |
Irving L Wiesen | director | 1273 NORTH AVENUE, APT 1E 7, NEW ROCHELLE NY 10804 |
Howard Spindel | director | 39 BROADWAY SUITE 3300, NEW YORK NY 10028 |
Nelida Plaza Rodriguez | officer: Vice President and Secretary | G11 CALLE MADRE PERLA URB, DORADO DEL MAR, DORADO PR 00646 |
Krovim Llc | director, 10 percent owner, officer: Manager | P.O. BOX 339, LAWRENCE NY 11559 |
From GuruFocus
By ACCESSWIRE • 01-30-2025
By [email protected] [email protected] • 06-16-2020
By ACCESSWIRE • 09-17-2024
By [email protected] [email protected] • 03-17-2020
By ACCESSWIRE ACCESSWIRE • 02-01-2021
By ACCESSWIRE • 01-30-2025
By ACCESSWIRE • 06-15-2024
By ACCESSWIRE ACCESSWIRE • 09-15-2021
By ACCESSWIRE • 03-18-2025
By ACCESSWIRE ACCESSWIRE • 02-12-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.